Workflow
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
HALOHalozyme(HALO) Prnewswire·2024-06-25 13:15

Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion. The SC injection was designed to be administered by healthcare professionals, with the flexibility to be administered either in the clinic or in settings outside the clinic. The EC approval is based on pivotal data from the Phase III OCARINA II trial, which showed non-inferior levels of ...